Illumina Inc.’s top executive said increasing reimbursement for genetic screening by insurers and the company’s lower prices have helped drive a surge in demand for its testing products.
“We’re seeing a lot of progress in the genomics market in terms of making tests more available,” Chief Executive Officer Francis deSouza said in a Bloomberg Television interview. “For instance, we’ve seen a massive increase in reimbursement for cancer patients to use genomic tests.”
